NCT01234051Unknown2 期
Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
Korean South West Oncology Group1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2010年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- Response rate
研究概览
简要总结
- Goals
- The primary goal of this phase II trial is to:
evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with locally advanced or metastatic BTC as first-line therapy
Secondary goals are to:evaluate the treatment-related toxicities of this combination, investigate progression-free survival (PFS) and overall survival (OS) in this population 2. Design
The proposed clinical trial is an open label, non-comparative, multicenter phase II trial according to the two stage testing design by Simon.22
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who were diagnosed as adenocarcinoma of gallbladder or biliary tract histologically or cytologically
- •Unresectable locally advanced, metastatic, or recurrent biliary tract cancer
- •Patients must be ≥ 18 years old of age
- •ECOG performance status ≤ 2 (see Appendix C)
- •At least one lesion that can be measured by imaging (CT/MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (see Appendix D)
- •Estimated life expectancy of more than 3 months
- •Adequate bone marrow function (absolute neutrophil count [ANC] ≥ 1,500/µL, hemoglobin ≥ 9.0 g/dL [correction by transfusion is acceptable], and platelets ≥ 100,000/µL)
- •Adequate kidney function (serum creatinine < 1.5 x upper limit of normal [ULN])
- •Adequate liver function (serum total bilirubin < 3xULN; serum transaminases levels < 5xUNL)
- •Provision of fully informed consent prior to any study specific procedures
排除标准
- •Other tumor type than adenocarcinoma
- •Any previous history of chemotherapy for biliary tract cancer (prior neoadjuvant/adjuvant chemotherapy is allowed, if recurrence occurred more than 6 months after completion of previous chemotherapy)
- •Patients with second primary cancer (except, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥5 years)
- •Patients who received radiotherapy on target lesion within 6 months prior to study treatment
- •Patients with defect of central nervous system (CNS) or any psychiatric disorders and CNS metastases
- •Patients who received major surgery within 4 weeks of starting study treatment or was not recovered from any effects of major surgery
- •Pregnant or breastfeeding women and women of childbearing potential not employing adequate contraception
- •Other serious illness or medical conditions A. Clinically significant cardiac disease (uncontrolled congestive heart disease despite treatment [NYHA class III or IV], symptomatic coronary artery disease, unstable angina or myocardial infarction, conduction abnormality like grade 2 AV block, serious arrhythmia needed for medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver cirrhosis (≥ Child-Pugh class B) C. History of significant neurologic or psychiatric disorders including dementia or seizures D. Active uncontrolled infection E. Other serious underlying medical conditions which could impair the ability of the patient to participate in the study
- •Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy
研究组 & 干预措施
Docetaxel, oxaliplatin, palliative chemotherapy
Experimental
干预措施: Docetaxel, Oxaliplatin (Drug)
结局指标
主要结局
Response rate
时间窗: 2years
次要结局
- Treatment-related toxicities(2 years)
- Progression free survival(2 years)
- Overall survival(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line TreatmentCarcinoma, Non-Small-Cell LungCarcinoma, SquamousCarcinoma, Large CellNCT01497041Korean South West Oncology Group35
已完成
2 期
Docetaxel in Non Small Cell Lung Cancer (NSCLC)Carcinoma, Squamous CellNCT00432315Sanofi80
已完成
2 期
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)Carcinoma, Non-small-cell LungNCT00406302Wolfgang Hilbe41
已完成
2 期
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial TractMetastatic Transitional Cell Cancer of the Urothelial TractNCT03159143Leonard Appleman22
已完成
1 期
Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate CancerProstate CancerNCT00559429Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins13